Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:FPRX Five Prime Therapeutics (FPRX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Five Prime Therapeutics Stock (NASDAQ:FPRX) 30 days 90 days 365 days Advanced Chart Ad Crypto 101 MediaBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Get FPRX alerts:Sign Up Key Stats Today's Range$38.00▼$38.0050-Day Range$37.65▼$38.0052-Week Range$2.61▼$38.90VolumeN/AAverage Volume1.98 million shsMarket Capitalization$1.77 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewFive Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase 3 clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that is in Phase 1a/1b clinical trial that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein, which is in Phase 1a/1b clinical trial that enhances co-stimulation of T cells through CD28. Its product candidates also include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with Opdivo. The company's BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase 1/2 clinical trial as a single agent and in combination with Opdivo in patients with advanced malignant tumors. It has license and collaboration agreements with Bristol-Myers Squibb Company, GlaxoSmithKline LLC, INBRX 110 LP, UCB Pharma S.A., and Zai Lab (Shanghai) Co., Ltd.; and license agreements with Galaxy Biotech, LLC, BioWa, Inc. and Lonza Sales AG. The company was founded in 2001 and is headquartered in South San Francisco, California.Read More… Blackrock’s Sending THIS Crypto Higher on Purpose (Ad)It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Receive FPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Five Prime Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address FPRX Stock News HeadlinesPlay Five Card Draw Online for Free | Yahoo! GamesAugust 9, 2024 | yahoo.comCMMB Chemomab Therapeutics Ltd.March 28, 2024 | seekingalpha.com2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.November 21, 2024 | Darwin (Ad)33+ best October Prime Day deals you can still shop right nowOctober 15, 2023 | nbcnews.comNK Cell Therapy Pipeline, Clinical Trials Studies, Emerging Drugs, and FDA Approvals 2023 (Updated)October 11, 2023 | benzinga.comThe Giants’ prime time TV demons are haunting them nowOctober 3, 2023 | nypost.comWhat Is The Prime Rate Today?August 3, 2023 | forbes.comWant $5? Amazon Prime members can get $5 off a $50 Amazon eGift Card right nowJuly 23, 2023 | usatoday.comSee More Headlines FPRX Stock Analysis - Frequently Asked Questions How were Five Prime Therapeutics' earnings last quarter? Five Prime Therapeutics, Inc. (NASDAQ:FPRX) released its earnings results on Friday, November, 6th. The biotechnology company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by $0.14. The biotechnology company had revenue of $2.05 million for the quarter, compared to the consensus estimate of $3.50 million. Five Prime Therapeutics had a negative trailing twelve-month return on equity of 75.84% and a negative net margin of 554.71%. Read the conference call transcript. What other stocks do shareholders of Five Prime Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Five Prime Therapeutics investors own include Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), OPKO Health (OPK), Pfizer (PFE), Nektar Therapeutics (NKTR), Advanced Micro Devices (AMD) and Inovio Pharmaceuticals (INO). Company Calendar Last Earnings11/06/2020Today11/21/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:FPRX CUSIPN/A CIK1175505 Webwww.fiveprime.com Phone415-365-5600FaxN/AEmployees87Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-137,200,000.00 Net Margins-554.71% Pretax MarginN/A Return on Equity-75.84% Return on Assets-49.08% Debt Debt-to-Equity RatioN/A Current Ratio5.35 Quick Ratio5.35 Sales & Book Value Annual Sales$14.87 million Price / Sales119.01 Cash FlowN/A Price / Cash FlowN/A Book Value$4.13 per share Price / Book9.20Miscellaneous Outstanding Shares46,572,000Free FloatN/AMarket Cap$1.77 billion OptionableOptionable Beta4.40 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:FPRX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Five Prime Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Five Prime Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.